- Home
- USA vs RCKT Comparison
USA vs RCKT Comparison
Compare USA & RCKT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- USA
- RCKT
- Stock Information
- Founded
- USA 1986
- RCKT 1999
- Country
- USA United States
- RCKT United States
- Employees
- USA N/A
- RCKT N/A
- Industry
- USA Finance Companies
- RCKT Biotechnology: Pharmaceutical Preparations
- Sector
- USA Finance
- RCKT Health Care
- Exchange
- USA Nasdaq
- RCKT Nasdaq
- Market Cap
- USA 1.9B
- RCKT 328.6M
- IPO Year
- USA N/A
- RCKT N/A
- Fundamental
- Price
- USA $6.50
- RCKT $3.17
- Analyst Decision
- USA
- RCKT Buy
- Analyst Count
- USA 0
- RCKT 13
- Target Price
- USA N/A
- RCKT $12.96
- AVG Volume (30 Days)
- USA 880.5K
- RCKT 2.8M
- Earning Date
- USA 01-01-0001
- RCKT 11-06-2025
- Dividend Yield
- USA 9.66%
- RCKT N/A
- EPS Growth
- USA N/A
- RCKT N/A
- EPS
- USA N/A
- RCKT N/A
- Revenue
- USA N/A
- RCKT N/A
- Revenue This Year
- USA N/A
- RCKT N/A
- Revenue Next Year
- USA N/A
- RCKT $108.43
- P/E Ratio
- USA N/A
- RCKT N/A
- Revenue Growth
- USA N/A
- RCKT N/A
- 52 Week Low
- USA $5.62
- RCKT $2.19
- 52 Week High
- USA $7.09
- RCKT $22.00
- Technical
- Relative Strength Index (RSI)
- USA 43.39
- RCKT 48.10
- Support Level
- USA $6.46
- RCKT $3.09
- Resistance Level
- USA $6.55
- RCKT $3.29
- Average True Range (ATR)
- USA 0.07
- RCKT 0.15
- MACD
- USA -0.01
- RCKT -0.02
- Stochastic Oscillator
- USA 23.89
- RCKT 37.94
About USA Liberty All-Star Equity Fund
Liberty All Star Equity Fund is a multi-managed fund. Its objective is to provide a high level of current income and long-term capital appreciation through investing principally in a diversified portfolio of equity securities. The fund invests in various sectors, including financials, information technology, healthcare, consumer discretionary, consumer staples, industrials, energy, materials, real estate, utilities, telecommunication, and other services.
About RCKT Rocket Pharmaceuticals Inc.
Rocket Pharmaceuticals Inc is a late-stage biopharmaceutical company. It is focused on the development of gene therapies for rare and devastating pediatric diseases. The pipeline products of the company include RP-A501 for Danaon Disease, RP-L102 for Fanconi Anemia, RP-L201 for Leukocyte Adhesion, RP-L301 for Pyruvate Kinase Deficiency, and RP-L401 for Infantile Malignant Osteopetrosis. The Company has one reportable segment related to R&D and commercial readiness of its gene therapies.